Maximal androgen blockade for advanced prostate cancer (Q30868300)

27 June 2017

1 reference

title

Maximal androgen blockade for advanced prostate cancer (English)

1 reference

27 June 2017

1 reference

B Schmitt

1

1 reference

27 June 2017

C Bennett

2

1 reference

27 June 2017

J Seidenfeld

3

1 reference

27 June 2017

D Samson

4

1 reference

27 June 2017

T Wilt

5

1 reference

27 June 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

published in

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

page(s)

CD001526

1 reference

Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Controversies in the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Gonadotropin-releasing hormone and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

21 January 2018

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001526

10.1002/14651858.CD001526

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference